https://news.medxy.ai/zh/%e6%97%a9%e6%9c%9f%e7%8e%af%e5%92%bd%e8%82%8c%e5%b9%b2%e9%a2%84%e5%8f%af%e8%83%bd%e6%94%b9%e5%96%84%e7%a5%9e%e7%bb%8f%e6%8d%9f%e4%bc%a4%e5%90%8e%e4%b8%8a%e9%a3%9f%e7%ae%a1%e6%8b%ac%e7%ba%a6%e8%82%8c/Medxy AIzh2026-05-20T13:09:59-07:00早期环咽肌干预可能改善神经损伤后上食管括约肌开放缺失患者的经口进食 https://news.medxy.ai/ja/%e6%97%a9%e6%9c%9f%e7%92%b0%e5%92%bd%e7%ad%8b%e6%89%8b%e8%a1%93%e4%bb%8b%e5%85%a5%e5%8f%af%e8%83%bd%e6%94%b9%e5%96%84%e7%a5%9e%e7%b5%8c%e9%9a%9c%e5%ae%b3%e5%be%8c%e3%81%ae%e4%b8%8a%e9%83%a8%e9%a3%9f/Medxy AIja2026-05-20T13:07:55-07:00早期環咽筋手術介入可能改善神経障害後の上部食道括約筋開放不全の経口摂取 https://news.medxy.ai/earlier-cricopharyngeal-intervention-may-improve-oral-intake-in-absent-ues-opening-after-neurological-injury/Medxy AIen2026-05-20T13:03:10-07:00Earlier Cricopharyngeal Intervention May Improve Oral Intake in Absent UES Opening After Neurological Injury https://news.medxy.ai/ja/%e6%b2%bb%e7%99%82%e3%81%b8%e3%81%ae%e4%b8%8d%e5%9d%87%e7%ad%89%e3%81%aa%e9%81%93-%e5%9c%b0%e5%9f%9f%e3%80%81%e8%be%b2%e6%9d%91%e6%80%a7%e3%80%81%e3%81%8a%e3%82%88%e3%81%b3%e5%89%a5%e5%a4%ba%e3%81%8c/Medxy AIja2026-05-20T13:01:30-07:00治療への不均等な道: 地域、農村性、および剥夺が重症外傷患者の認定外傷センターや運送に与える影響 https://news.medxy.ai/vi/con-duong-cham-soc-khong-dong-deu-cach-khu-vuc-nong-thon-va-su-tuoc-quyen-anh-huong-den-viec-van-chuyen-den-cac-trung-tam-chan-thuong-da-xac-minh-cho-nhung-benh-nhan-bi-chan-thuong-nghiem-trong/Medxy AIvi2026-05-20T12:59:55-07:00Con đường chăm sóc không đồng đều: Cách khu vực, nông thôn và sự tước quyền ảnh hưởng đến việc vận chuyển đến các trung tâm chấn thương đã xác minh cho những bệnh nhân bị chấn thương nghiêm trọng https://news.medxy.ai/unequal-paths-to-care-how-region-rurality-and-deprivation-shape-transport-to-verified-trauma-centers-among-the-critically-injured/Medxy AIen2026-05-20T12:57:42-07:00Unequal Paths to Care: How Region, Rurality, and Deprivation Shape Transport to Verified Trauma Centers Among the Critically Injured https://news.medxy.ai/higher-fidelity-enhanced-recovery-shortened-stay-and-reduced-complications-in-children-undergoing-gi-surgery-even-though-the-overall-trial-was-neutral/Medxy AIen2026-05-20T12:43:30-07:00Higher-Fidelity Enhanced Recovery Shortened Stay and Reduced Complications in Children Undergoing GI Surgery, Even Though the Overall Trial Was Neutral https://news.medxy.ai/ja/abrupt2%e8%a9%a6%e9%a8%93%ef%bc%9a5%e3%82%a2%e3%83%ab%e3%83%96%e3%83%9f%e3%83%b3%e3%81%8c%e5%a4%a7%e8%a6%8f%e6%a8%a1%e3%82%84%e3%81%91%e3%81%a9%e8%98%87%e7%94%9f%e6%99%82%e3%81%ae%e8%bc%b8%e6%b6%b2/Medxy AIja2026-05-20T12:25:40-07:00ABRUPT2試験：5%アルブミンが大規模やけど蘇生時の輸液量を減少させた https://news.medxy.ai/vi/thu-nghiem-abrupt2-5-albumin-giam-yeu-cau-dung-dich-trong-phuc-hoi-chan-thuong-nghiem-trong/Medxy AIvi2026-05-20T12:24:10-07:00Thử nghiệm ABRUPT2: 5% Albumin Giảm Yêu Cầu Dung Dịch trong Phục Hồi Chấn Thương Nghiêm Trọng https://news.medxy.ai/abrupt2-trial-5-albumin-reduced-fluid-requirements-in-major-burn-resuscitation/Medxy AIen2026-05-20T12:22:10-07:00ABRUPT2 Trial: 5% Albumin Reduced Fluid Requirements in Major Burn Resuscitation https://news.medxy.ai/ja/%e3%82%a2%e3%83%a1%e3%83%aa%e3%82%ab%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8bfigo-2014%e5%b9%b4iii-iva%e6%9c%9f%e5%ad%90%e5%ae%ae%e9%a0%b8%e3%81%8c%e3%82%93%e3%81%ab%e5%af%be%e3%81%99%e3%82%8b%e3%83%9a/Medxy AIja2026-05-20T11:59:54-07:00アメリカにおけるFIGO 2014年III-IVA期子宮頸がんに対するペムブロリズマブの費用対効果 https://news.medxy.ai/vi/hieu-qua-kinh-te-cua-pembrolizumab-trong-dieu-tri-ung-thu-co-tu-cung-giai-doan-iii-iva-theo-figo-2014-tai-hoa-ky/Medxy AIvi2026-05-20T11:58:17-07:00Hiệu quả kinh tế của Pembrolizumab trong điều trị ung thư cổ tử cung giai đoạn III-IVA theo FIGO 2014 tại Hoa Kỳ https://news.medxy.ai/cost-effectiveness-of-pembrolizumab-for-figo-2014-stage-iii-iva-cervical-cancer-in-the-united-states/Medxy AIen2026-05-20T11:56:37-07:00Cost-effectiveness of Pembrolizumab for FIGO 2014 Stage III-IVA Cervical Cancer in the United States https://news.medxy.ai/ja/%e5%a4%9a%e5%9b%8a%e5%8d%b5%e5%b7%a2%e7%bb%bc%e5%90%88%e5%be%81%e4%b8%ad%e5%ad%90%e5%ae%ab%e5%86%85%e8%86%9c%e5%8a%9f%e8%83%bd%e9%9a%9c%e7%a2%8d%e7%9a%84%e5%be%ae%e7%94%9f%e7%89%a9%e5%92%8c%e4%bb%a3/Medxy AIja2026-05-20T11:53:42-07:00多囊卵巢综合征中子宫内膜功能障碍的微生物和代谢相关因素：一项转化研究 https://news.medxy.ai/vi/cac-yeu-to-vi-sinh-va-chuyen-hoa-lien-quan-den-roi-loan-noi-mac-tu-cung-trong-hoi-chung-buong-trung-da-nang-mot-nghien-cuu-dich-te-hoc/Medxy AIvi2026-05-20T11:52:26-07:00Các yếu tố vi sinh và chuyển hóa liên quan đến rối loạn nội mạc tử cung trong hội chứng buồng trứng đa nang: Một nghiên cứu dịch tễ học https://news.medxy.ai/microbial-and-metabolic-correlates-of-endometrial-dysfunction-in-polycystic-ovary-syndrome-a-translational-study/Medxy AIen2026-05-20T11:50:04-07:00Microbial and Metabolic Correlates of Endometrial Dysfunction in Polycystic Ovary Syndrome: A Translational Study https://news.medxy.ai/ja/%e5%88%86%e5%a8%a9%e3%81%a8%e5%b8%9d%e7%8e%8b%e5%88%87%e9%96%8b%e5%be%8c%e3%81%ae%e8%a9%a6%e9%a8%93%e5%8a%b4%e5%83%8d%e3%81%ae%e4%bd%bf%e7%94%a8%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8b%e4%ba%ba%e7%a8%ae/Medxy AIja2026-05-20T11:31:56-07:00分娩と帝王切開後の試験労働の使用における人種的分離の影響 https://news.medxy.ai/vi/moi-lien-he-giua-phan-biet-chung-toc-trong-dich-vu-sinh-no-va-viec-su-dung-thu-nghiem-chuyen-da-sau-mo-lay-thai-va-sinh-thuong-sau-mo-lay-thai/Medxy AIvi2026-05-20T11:30:46-07:00Mối liên hệ giữa phân biệt chủng tộc trong dịch vụ sinh nở và việc sử dụng thử nghiệm chuyển dạ sau mổ lấy thai và sinh thường sau mổ lấy thai https://news.medxy.ai/association-between-racial-segregation-of-labor-and-delivery-services-and-use-of-trial-of-labor-and-vaginal-birth-after-cesarean/Medxy AIen2026-05-20T11:29:05-07:00Association Between Racial Segregation of Labor and Delivery Services and Use of Trial of Labor and Vaginal Birth After Cesarean https://news.medxy.ai/ja/%e7%b3%96%e5%b0%bf%e7%97%85%e3%80%81%e7%94%b7%e6%80%a7%e6%80%a7%e5%88%a5%e3%80%81%e4%bd%8ehbsag%e3%80%81hdv-rna%e3%80%81alt%e4%ba%88%e6%b8%ac%e6%85%a2%e6%80%a7d%e5%9e%8b%e8%82%9d%e7%82%8e%e8%87%aa/Medxy AIja2026-05-20T11:25:38-07:00糖尿病、男性性別、低HBsAg、HDV RNA、ALT予測慢性D型肝炎自発的HDV抑制 https://news.medxy.ai/vi/dai-thao-duong-gioi-tinh-nam-va-nong-do-hbsag-hdv-rna-alt-thap-du-doan-su-uc-che-tu-nhien-cua-hdv-trong-viem-gan-d-man-tinh/Medxy AIvi2026-05-20T11:24:23-07:00Đái tháo đường, giới tính nam và nồng độ HBsAg, HDV RNA, ALT thấp dự đoán sự ức chế tự nhiên của HDV trong viêm gan D mạn tính https://news.medxy.ai/diabetes-male-sex-and-low-hbsag-hdv-rna-and-alt-predict-spontaneous-hdv-suppression-in-chronic-hepatitis-d/Medxy AIen2026-05-20T11:22:40-07:00Diabetes, Male Sex, and Low HBsAg, HDV RNA, and ALT Predict Spontaneous HDV Suppression in Chronic Hepatitis D https://news.medxy.ai/targeting-mlck1-may-separate-immune-checkpoint-inhibitor-colitis-from-antitumour-benefit/Medxy AIen2026-05-20T11:03:28-07:00Targeting MLCK1 May Separate Immune Checkpoint Inhibitor Colitis From Antitumour Benefit https://news.medxy.ai/ja/%e8%84%b3%e5%8d%92%e4%b8%ad%e5%be%8c%e3%81%ae%e9%95%b7%e6%9c%9f%e8%aa%8d%e7%9f%a5%e5%9b%9e%e5%be%a9%ef%bc%9a%e3%82%aa%e3%83%83%e3%82%af%e3%82%b9%e3%83%95%e3%82%a9%e3%83%bc%e3%83%89%e8%aa%8d%e7%9f%a5/Medxy AIja2026-05-20T11:01:49-07:00脳卒中後の長期認知回復：オックスフォード認知スクリーニングの示すもの https://news.medxy.ai/vi/phuc-hoi-nhan-thuc-dai-han-sau-dot-quy-dieu-ma-bang-danh-gia-nhan-thuc-oxford-tiet-lo/Medxy AIvi2026-05-20T11:00:19-07:00Phục hồi nhận thức dài hạn sau đột quỵ: Điều mà Bảng đánh giá nhận thức Oxford tiết lộ https://news.medxy.ai/long-term-cognitive-recovery-after-stroke-what-the-oxford-cognitive-screen-reveals/Medxy AIen2026-05-20T10:58:18-07:00Long-Term Cognitive Recovery After Stroke: What the Oxford Cognitive Screen Reveals https://news.medxy.ai/ja/%e6%97%a9%e6%9c%9f%e3%83%91%e3%83%bc%e3%82%ad%e3%83%b3%e3%82%bd%e3%83%b3%e7%97%85%e3%81%ab%e5%af%be%e3%81%99%e3%82%8b%e5%ae%9a%e7%94%a8%e9%87%8f%e3%82%bf%e3%83%90%e3%83%91%e3%83%89%e3%83%b3%ef%bc%9a/Medxy AIja2026-05-20T10:33:37-07:00早期パーキンソン病に対する定用量タバパドン：無作為化臨床試験 https://news.medxy.ai/vi/tavapadon-lieu-co-dinh-cho-benh-parkinson-som-mot-thu-nghiem-lam-sang-ngau-nhien/Medxy AIvi2026-05-20T10:32:06-07:00Tavapadon liều cố định cho bệnh Parkinson sớm: Một thử nghiệm lâm sàng ngẫu nhiên https://news.medxy.ai/fixed-dose-tavapadon-for-early-parkinson-disease-a-randomized-clinical-trial/Medxy AIen2026-05-20T10:30:37-07:00Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial https://news.medxy.ai/ja/%e7%94%b2%e7%8a%b6%e8%85%ba%e5%88%87%e9%99%a4%e8%a1%93%e5%be%8c%e3%81%ae%e7%96%b2%e5%8a%b4-%e6%82%a3%e8%80%85%e3%81%8c%e5%ae%9f%e9%9a%9b%e3%81%ab%e7%b5%8c%e9%a8%93%e3%81%99%e3%82%8b%e3%81%93%e3%81%a8/Medxy AIja2026-05-20T10:28:50-07:00甲状腺切除術後の疲労: 患者が実際に経験すること https://news.medxy.ai/zh/%e7%94%b2%e7%8a%b6%e8%85%ba%e5%88%87%e9%99%a4%e6%9c%af%e5%90%8e%e7%96%b2%e5%8a%b3%ef%bc%9a%e6%82%a3%e8%80%85%e7%9a%84%e5%ae%9e%e9%99%85%e4%bd%93%e9%aa%8c/Medxy AIzh2026-05-20T10:27:34-07:00甲状腺切除术后疲劳：患者的实际体验 https://news.medxy.ai/fatigue-after-thyroidectomy-what-patients-actually-experience/Medxy AIen2026-05-20T10:26:27-07:00Fatigue After Thyroidectomy: What Patients Actually Experience https://news.medxy.ai/zh/%e8%83%b0%e5%b2%9b%ce%b2%e7%bb%86%e8%83%9e%e5%8d%8f%e5%90%8c%e4%bf%9d%e6%8a%a4%ef%bc%9aglp1-e2%e4%b8%8e%e4%bd%8e%e5%89%82%e9%87%8f%e6%8a%97cd3%e8%81%94%e5%90%88%e7%96%97%e6%b3%95%e5%9c%a8%e8%87%aa/Medxy AIzh2026-05-20T10:20:50-07:00胰岛β细胞协同保护：GLP1-E2与低剂量抗CD3联合疗法在自身免疫性糖尿病中的应用 https://news.medxy.ai/ja/%e8%86%b5%ce%b2%e7%b4%b0%e8%83%9e%e3%81%ae%e7%9b%b8%e4%b9%97%e4%bf%9d%e8%ad%b7%ef%bc%9aglp1-e2%e3%81%a8%e4%bd%8e%e7%94%a8%e9%87%8f%e6%8a%97cd3%e4%bd%b5%e7%94%a8%e7%99%82%e6%b3%95%e3%81%ab%e3%82%88/Medxy AIja2026-05-20T10:19:48-07:00膵β細胞の相乗保護：GLP1-E2と低用量抗CD3併用療法による自己免疫性糖尿病の治療 https://news.medxy.ai/vi/bao-ve-phoi-hop-te-bao-%ce%b2-tuy-lieu-phap-ket-hop-glp1-e2-va-anti-cd3-lieu-thap-trong-dai-thao-duong-tu-mien/Medxy AIvi2026-05-20T10:18:17-07:00Bảo vệ phối hợp tế bào β tụy: liệu pháp kết hợp GLP1-E2 và anti-CD3 liều thấp trong đái tháo đường tự miễn https://news.medxy.ai/synergistic-protection-of-pancreatic-beta-cells-glp1-e2-and-low-dose-anti-cd3-combination-therapy-in-autoimmune-diabetes/Medxy AIen2026-05-20T10:15:42-07:00Synergistic Protection of Pancreatic Beta Cells: GLP1-E2 and Low-Dose Anti-CD3 Combination Therapy in Autoimmune Diabetes https://news.medxy.ai/ja/%e5%b0%8f%e5%85%90%e6%9c%9f%e3%81%aesga%e5%85%90%e3%81%ae%e6%88%90%e9%95%b7%e3%83%9b%e3%83%ab%e3%83%a2%e3%83%b3%e6%b2%bb%e7%99%82%e3%81%af%e3%80%81%e8%82%a5%e6%ba%80%e5%85%90%e3%81%a8%e5%90%8c/Medxy AIja2026-05-19T14:18:46-07:00小児期のSGA児の成長ホルモン治療は、肥満児と同様にグルコース-インスリン代謝が障害される https://news.medxy.ai/vi/tre-sinh-ra-voi-can-nang-thap-hon-tuoi-thai-duoc-dieu-tri-bang-hormone-tang-truong-co-su-roi-loan-chuyen-hoa-glucose-insulin-tuong-tu-nhu-tre-beo-phi/Medxy AIvi2026-05-19T14:17:09-07:00Trẻ sinh ra với cân nặng thấp hơn tuổi thai được điều trị bằng hormone tăng trưởng có sự rối loạn chuyển hóa glucose-insulin tương tự như trẻ béo phì https://news.medxy.ai/children-born-sga-receiving-growth-hormone-have-similarly-impaired-glucose-insulin-metabolism-as-children-with-obesity/Medxy AIen2026-05-19T14:15:16-07:00Children Born SGA Receiving Growth Hormone Have Similarly Impaired Glucose-Insulin Metabolism as Children With Obesity https://news.medxy.ai/ja/%e8%a1%80%e6%b6%b2%e4%b8%admtdna%e3%82%b3%e3%83%94%e3%83%bc%e6%95%b0%e3%81%a82%e5%9e%8b%e7%b3%96%e5%b0%bf%e7%97%85%e3%81%ae%e3%83%aa%e3%82%b9%e3%82%af%e3%81%a8%e3%81%aeu%e5%ad%97%e5%9e%8b%e9%96%a2/Medxy AIja2026-05-19T12:26:37-07:00血液中mtDNAコピー数と2型糖尿病のリスクとのU字型関連 https://news.medxy.ai/vi/su-lien-quan-dang-u-giua-so-ban-sao-mtdna-trong-mau-va-nguy-co-bi-benh-dai-thao-duong-loai-2/Medxy AIvi2026-05-19T12:24:40-07:00Sự Liên Quan Dạng U Giữa Số Bản Sao mtDNA Trong Máu và Nguy Cơ Bị Bệnh Đái Tháo Đường Loại 2 https://news.medxy.ai/a-u-shaped-association-between-blood-mtdna-copy-number-and-risk-of-type-2-diabetes/Medxy AIen2026-05-19T12:22:12-07:00A U-Shaped Association Between Blood mtDNA Copy Number and Risk of Type 2 Diabetes https://news.medxy.ai/cardiogenic-shock-care-still-varies-widely-across-cicus-especially-in-the-choice-of-inodilators/Medxy AIen2026-05-19T12:01:30-07:00Cardiogenic Shock Care Still Varies Widely Across CICUs, Especially in the Choice of Inodilators https://news.medxy.ai/validated-emperor-preserved-risk-models-stratify-prognosis-in-finearts-hf-while-finerenone-benefits-remain-consistent-across-baseline-risk/Medxy AIen2026-05-19T11:59:12-07:00Validated EMPEROR-Preserved Risk Models Stratify Prognosis in FINEARTS-HF, While Finerenone Benefits Remain Consistent Across Baseline Risk https://news.medxy.ai/ja/%e5%bf%83%e4%b8%8d%e5%85%a8%e3%81%ae%e5%b0%84%e8%a1%80%e5%88%86%e6%95%b0%e3%81%8c%e4%bd%8e%e4%b8%8b%e3%80%81%e8%bb%bd%e5%ba%a6%e4%bd%8e%e4%b8%8b%e3%80%81%e3%81%be%e3%81%9f%e3%81%af%e6%ad%a3%e5%b8%b8/Medxy AIja2026-05-19T11:58:09-07:00心不全の射血分数が低下、軽度低下、または正常のアウトカム：ESC HF III レジストリ https://news.medxy.ai/vi/ket-qua-cua-suy-tim-voi-phan-suat-tong-mau-giam-giam-nhe-hoac-bao-ton-dang-ky-esc-hf-iii/Medxy AIvi2026-05-19T11:56:49-07:00Kết quả của suy tim với phân suất tống máu giảm, giảm nhẹ hoặc bảo tồn: Đăng ký ESC HF III https://news.medxy.ai/outcomes-of-heart-failure-with-reduced-mildly-reduced-or-preserved-ejection-fraction-esc-hf-iii-registry/Medxy AIen2026-05-19T11:54:22-07:00Outcomes of Heart Failure With Reduced, Mildly Reduced, or Preserved Ejection Fraction: ESC HF III Registry https://news.medxy.ai/ja/%e5%a4%9a%e5%8b%95%e8%84%88%e3%83%90%e3%82%a4%e3%83%91%e3%82%b9%e3%81%a8%e5%86%a0%e5%8b%95%e8%84%88%e3%83%90%e3%82%a4%e3%83%91%e3%82%b9%e8%a1%93%e5%be%8c%e3%81%ae%e7%94%9f%e5%ad%98%e7%8e%87-%e5%99%a8/Medxy AIja2026-05-19T11:44:28-07:00多動脈バイパスと冠動脈バイパス術後の生存率: 器具変数分析 https://news.medxy.ai/vi/cay-ghep-da-dong-mach-va-su-song-sot-sau-cay-ghep-dong-mach-vanh-phan-tich-bien-so-cong-cu/Medxy AIvi2026-05-19T11:42:33-07:00Cấy ghép đa động mạch và sự sống sót sau cấy ghép động mạch vành: Phân tích biến số công cụ https://news.medxy.ai/multiarterial-grafting-and-survival-after-coronary-artery-bypass-grafting-an-instrumental-variable-analysis/Medxy AIen2026-05-19T11:40:06-07:00Multiarterial Grafting and Survival After Coronary Artery Bypass Grafting: An Instrumental Variable Analysis https://news.medxy.ai/ja/%e4%bb%a5%e5%89%8d%e3%81%ae%e7%b5%8c%e7%9a%ae%e7%9a%84%e5%86%a0%e5%8b%95%e8%84%88%e4%bb%8b%e5%85%a5%e6%b2%bb%e7%99%82%e3%82%92%e5%8f%97%e3%81%91%e3%81%9f%e3%81%8c%e5%bf%83%e7%ad%8b%e6%a2%97%e5%a1%9e/Medxy AIja2026-05-19T11:25:53-07:00以前の経皮的冠動脈介入治療を受けたが心筋梗塞の既往がない患者におけるエボロクマブ：VESALIUS-CV試験の結果 https://news.medxy.ai/vi/evolocumab-o-benh-nhan-da-thuc-hien-can-thiep-dong-mach-vanh-qua-da-va-chua-tung-co-nhoi-mau-co-tim-ket-qua-tu-thu-nghiem-vesalius-cv/Medxy AIvi2026-05-19T11:24:14-07:00Evolocumab ở Bệnh Nhân Đã Thực Hiện Can thiệp Động mạch vành qua Da và Chưa Từng Có Nhồi máu cơ tim: Kết quả từ Thử nghiệm VESALIUS-CV https://news.medxy.ai/evolocumab-in-patients-with-prior-percutaneous-coronary-intervention-and-no-prior-mi-results-from-the-vesalius-cv-trial/Medxy AIen2026-05-19T11:22:06-07:00Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial https://news.medxy.ai/zh/%e6%9c%af%e5%89%8d%e6%94%be%e7%96%97%e5%89%82%e9%87%8f%e5%87%8f%e5%b0%91%e8%87%b336-gy%e5%9c%a8%e9%bb%8f%e6%b6%b2%e6%80%a7%e8%84%82%e8%82%aa%e8%82%89%e7%98%a4%e4%b8%ad%e7%bb%b4%e6%8c%81%e9%95%bf/Medxy AIzh2026-05-19T11:19:44-07:00术前放疗剂量减少至36 Gy在黏液性脂肪肉瘤中维持长期局部控制 https://news.medxy.ai/ja/%e8%a1%93%e5%89%8d%e6%94%be%e5%b0%84%e7%b7%9a%e7%99%82%e6%b3%95%e3%82%9236-gy%e3%81%ab%e5%89%8a%e6%b8%9b%e3%81%97%e3%81%a6%e3%82%82%e7%b2%98%e6%b6%b2%e6%80%a7%e8%84%82%e8%82%aa%e8%82%89%e8%85%ab/Medxy AIja2026-05-19T11:17:50-07:00術前放射線療法を36 Gyに削減しても粘液性脂肪肉腫の長期局所制御は良好を維持 https://news.medxy.ai/vi/giam-lieu-xa-tri-tien-phau-thuat-xuong-36-gy-duy-tri-kiem-soat-cuc-bo-dai-han-xuat-sac-trong-liposarcoma-nhay/Medxy AIvi2026-05-19T11:14:40-07:00Giảm liều xạ trị tiền phẫu thuật xuống 36 Gy duy trì kiểm soát cục bộ dài hạn xuất sắc trong liposarcoma nhầy https://news.medxy.ai/reduced-preoperative-radiotherapy-to-36-gy-maintains-excellent-long-term-local-control-in-myxoid-liposarcoma/Medxy AIen2026-05-19T11:10:43-07:00Reduced Preoperative Radiotherapy to 36 Gy Maintains Excellent Long-Term Local Control in Myxoid Liposarcoma https://news.medxy.ai/ja/%e9%9b%a3%e6%b2%bb%e6%80%a7%e5%a4%a7%e3%81%86%e3%81%a4%e7%97%85%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8b%e3%82%b7%e3%83%ad%e3%82%b7%e3%83%93%e3%83%b3%e3%81%ae%e6%9c%89%e5%8a%b9%e6%80%a7%e3%81%a8%e5%ae%89/Medxy AIja2026-05-19T00:22:53-07:00難治性大うつ病におけるシロシビンの有効性と安全性: EPISODE ランダム化比較試験 https://news.medxy.ai/vi/hieu-qua-va-an-toan-cua-psilocybin-trong-dieu-tri-tram-cam-trong-muc-khang-tri-thu-nghiem-lam-sang-ngau-nhien-episode/Medxy AIvi2026-05-19T00:20:51-07:00Hiệu quả và An toàn của Psilocybin trong Điều trị Trầm cảm Trọng mức Kháng trị: Thử nghiệm lâm sàng ngẫu nhiên EPISODE https://news.medxy.ai/efficacy-and-safety-of-psilocybin-in-treatment-resistant-major-depression-the-episode-randomized-clinical-trial/Medxy AIen2026-05-19T00:18:11-07:00Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial https://news.medxy.ai/ja/%e5%8c%bb%e7%99%82%e8%b2%bb%e3%81%ae%e6%94%af%e6%89%95%e3%81%84%e5%9b%b0%e9%9b%a3%ef%bc%9aicu%e4%bb%8b%e8%ad%b7%e8%80%85%e3%81%ae%e5%bf%83%e7%90%86%e7%9a%84%e8%8b%a6%e6%82%a9%e3%81%a8%e5%8c%bb/Medxy AIja2026-05-18T20:33:58-07:00医療費の支払い困難：ICU介護者の心理的苦悩と医療への認識との関連 https://news.medxy.ai/vi/kho-khan-trong-viec-thanh-toan-chi-phi-y-te-lien-ket-voi-roi-loan-tam-ly-va-nhan-thuc-ve-cham-soc-y-te-trong-so-nguoi-cham-soc-o-khoa-hoi-suc-tich-cuc/Medxy AIvi2026-05-18T20:32:20-07:00Khó khăn trong việc thanh toán chi phí y tế: Liên kết với rối loạn tâm lý và nhận thức về chăm sóc y tế trong số người chăm sóc ở Khoa Hồi sức tích cực https://news.medxy.ai/difficulty-paying-for-medical-care-links-to-psychological-distress-and-healthcare-perceptions-among-icu-caregivers/Medxy AIen2026-05-18T20:30:09-07:00Difficulty Paying for Medical Care: Links to Psychological Distress and Healthcare Perceptions Among ICU Caregivers https://news.medxy.ai/zh/%e6%80%a5%e8%af%8a%e7%a7%91%e5%a4%8d%e5%90%88%e8%82%ba%e6%a0%93%e5%a1%9e%e4%bc%91%e5%85%8b%e8%af%84%e5%88%86%e4%b8%8e%e7%9f%ad%e6%9c%9f%e4%b8%b4%e5%ba%8a%e7%bb%93%e5%b1%80%e7%9a%84%e7%9b%b8%e5%85%b3/Medxy AIzh2026-05-18T20:18:35-07:00急诊科复合肺栓塞休克评分与短期临床结局的相关性 https://news.medxy.ai/vi/moi-lien-quan-cua-diem-so-tong-hop-soc-do-thuyen-tac-phoi-tai-khoa-cap-cuu-voi-cac-ket-qua-lam-sang-ngan-han/Medxy AIvi2026-05-18T20:17:40-07:00Mối liên quan của điểm số tổng hợp sốc do thuyên tắc phổi tại khoa cấp cứu với các kết quả lâm sàng ngắn hạn https://news.medxy.ai/associations-of-the-composite-pulmonary-embolism-shock-score-in-the-emergency-department-with-short-term-clinical-outcomes/Medxy AIen2026-05-18T20:15:18-07:00Associations of the Composite Pulmonary Embolism Shock Score in the Emergency Department With Short-Term Clinical Outcomes https://news.medxy.ai/ja/%e7%97%85%e9%99%a2%e3%81%a7%e3%81%ae%e4%b8%8d%e9%81%a9%e5%88%87%e3%81%aa%e3%82%a2%e3%83%ab%e3%82%b3%e3%83%bc%e3%83%ab%e4%bd%bf%e7%94%a8%e3%81%ae%e3%82%b9%e3%82%af%e3%83%aa%e3%83%bc%e3%83%8b%e3%83%b3/Medxy AIja2026-05-18T19:50:13-07:00病院での不適切なアルコール使用のスクリーニングと治療プログラムの実施 https://news.medxy.ai/vi/thuc-hien-chuong-trinh-sang-loc-va-dieu-tri-dua-tren-benh-vien-cho-viec-su-dung-ruou-khong-lanh-manh/Medxy AIvi2026-05-18T19:48:38-07:00Thực hiện Chương trình sàng lọc và điều trị dựa trên bệnh viện cho việc sử dụng rượu không lành mạnh https://news.medxy.ai/ja/%e8%a8%aa%e5%95%8f%e6%99%82%e9%96%93%e5%9c%a7%e5%8a%9b%e3%81%8c%e8%bb%bd%e6%b8%9b%e3%81%95%e3%82%8c%e3%81%9f%e4%b8%80%e6%ac%a1%e5%8c%bb%e7%99%82%e3%81%ae%e6%8f%90%e4%be%9b/Medxy AIja2026-05-18T19:46:46-07:00訪問時間圧力が軽減された一次医療の提供 https://news.medxy.ai/implementation-of-a-hospital-based-screening-and-treatment-program-for-unhealthy-alcohol-use/Medxy AIen2026-05-18T19:46:41-07:00Implementation of a Hospital-Based Screening and Treatment Program for Unhealthy Alcohol Use https://news.medxy.ai/vi/cung-cap-cham-soc-co-ban-duoi-ap-luc-thoi-gian-giam/Medxy AIvi2026-05-18T19:45:13-07:00Cung cấp chăm sóc cơ bản dưới áp lực thời gian giảm https://news.medxy.ai/provision-of-primary-care-under-reduced-visit-time-pressures/Medxy AIen2026-05-18T19:42:57-07:00Provision of Primary Care Under Reduced Visit Time Pressures https://news.medxy.ai/vi/cham-soc-tu-xa-sau-dai-dich-ai-duoc-loi-dieu-gi-thay-doi-va-tuong-lai-se-ra-sao/Medxy AIvi2026-05-18T19:08:34-07:00Chăm sóc từ xa sau đại dịch: Ai được lợi, điều gì thay đổi, và tương lai sẽ ra sao https://news.medxy.ai/ja/%e3%83%91%e3%83%b3%e3%83%87%e3%83%9f%e3%83%83%e3%82%af%e5%be%8c%e3%81%ae%e9%81%a0%e9%9a%94%e5%8c%bb%e7%99%82-%e8%aa%b0%e3%81%8c%e6%81%a9%e6%81%b5%e3%82%92%e5%8f%97%e3%81%91%e3%80%81%e4%bd%95%e3%81%8c/Medxy AIja2026-05-18T19:06:49-07:00パンデミック後の遠隔医療: 誰が恩恵を受け、何が変わったのか、次に何が来るのか https://news.medxy.ai/zh/%e7%96%ab%e6%83%85%e5%90%8e%e7%9a%84%e8%bf%9c%e7%a8%8b%e5%8c%bb%e7%96%97%ef%bc%9a%e8%b0%81%e5%8f%97%e7%9b%8a%ef%bc%8c%e6%9c%89%e4%bd%95%e5%8f%98%e5%8c%96%ef%bc%8c%e6%9c%aa%e6%9d%a5%e4%bd%95%e5%9c%a8/Medxy AIzh2026-05-18T19:03:35-07:00疫情后的远程医疗：谁受益，有何变化，未来何在 https://news.medxy.ai/telemedicine-after-the-pandemic-who-benefits-what-changed-and-what-comes-next/Medxy AIen2026-05-18T19:00:32-07:00Telemedicine After the Pandemic: Who Benefits, What Changed, and What Comes Next https://news.medxy.ai/ja/%e7%ac%ac2%e5%8c%96%e5%ad%a6%e7%99%82%e6%b3%95%e3%82%b5%e3%82%a4%e3%82%af%e3%83%ab%e5%be%8c%e3%81%aecbfbmyh11-mrd%ef%bc%9a%e5%a5%bd%e7%99%ba%e3%83%aa%e3%82%b9%e3%82%af%e3%81%ae%e6%80%a5%e6%80%a7/Medxy AIja2026-05-18T18:18:35-07:00第2化学療法サイクル後のCBFB::MYH11 MRD：好発リスクの急性骨髄性白血病における同種造血細胞移植のガイド https://news.medxy.ai/vi/cbfbmyh11-mrd-sau-chu-ky-hoa-tri-thu-hai-huong-dan-cay-ghep-te-bao-goc-dong-loai-trong-aml-nguy-co-thuan-loi/Medxy AIvi2026-05-18T18:16:50-07:00CBFB::MYH11 MRD sau chu kỳ hóa trị thứ hai: Hướng dẫn cấy ghép tế bào gốc đồng loại trong AML nguy cơ thuận lợi https://news.medxy.ai/cbfbmyh11-mrd-after-the-second-chemotherapy-cycle-a-guide-to-allogeneic-transplantation-in-favorable-risk-aml/Medxy AIen2026-05-18T18:14:42-07:00CBFB::MYH11 MRD After the Second Chemotherapy Cycle: A Guide to Allogeneic Transplantation in Favorable-Risk AML https://news.medxy.ai/ja/nup98%e5%86%8d%e9%85%8d%e5%88%97%e3%82%92%e6%8c%81%e3%81%a4%e6%88%90%e4%ba%ba%e6%80%a5%e6%80%a7%e9%aa%a8%e9%ab%84%e6%80%a7%e7%99%bd%e8%a1%80%e7%97%85%e3%81%ae%e5%8c%85%e6%8b%ac%e7%9a%84%e3%81%aa/Medxy AIja2026-05-18T17:44:30-07:00NUP98再配列を持つ成人急性骨髄性白血病の包括的な突然変異プロファイルと臨床結果 https://news.medxy.ai/vi/xet-nghiem-dot-bien-toan-dien-va-ket-qua-lam-sang-o-nguoi-lon-mac-benh-bach-cau-cap-tinh-tuy-aml-co-su-sap-xep-lai-cua-gen-nup98/Medxy AIvi2026-05-18T17:42:56-07:00Xét nghiệm đột biến toàn diện và kết quả lâm sàng ở người lớn mắc bệnh bạch cầu cấp tính tủy (AML) có sự sắp xếp lại của gen NUP98 https://news.medxy.ai/comprehensive-mutational-profiling-and-clinical-outcomes-in-adult-aml-with-nup98-rearrangement/Medxy AIen2026-05-18T17:40:22-07:00Comprehensive Mutational Profiling and Clinical Outcomes in Adult AML with NUP98 Rearrangement https://news.medxy.ai/ja/%e3%83%af%e3%83%ab%e3%83%87%e3%83%b3%e3%82%b9%e3%83%88%e3%83%ac%e3%83%bc%e3%83%a0%e5%b7%a8%e7%90%83%e8%9b%8b%e7%99%bd%e8%a1%80%e7%97%87%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8b%e3%82%a4%e3%83%96%e3%83%aa/Medxy AIja2026-05-18T17:33:17-07:00ワルデンストレーム巨球蛋白血症におけるイブリチニブ反応の可変性を下支えする腫瘍サブクローンの進化とT細胞動態 https://news.medxy.ai/vi/su-tien-hoa-cua-cac-tieu-clone-khoi-u-va-dong-luc-te-bao-t-la-nguyen-nhan-gay-ra-su-phan-ung-khac-nhau-cua-ibrutinib-trong-benh-waldenstrom-macroglobulinemia/Medxy AIvi2026-05-18T17:31:47-07:00Sự tiến hóa của các tiểu clone khối u và động lực tế bào T là nguyên nhân gây ra sự phản ứng khác nhau của ibrutinib trong bệnh Waldenström macroglobulinemia https://news.medxy.ai/evolution-of-tumor-subclones-and-t-cell-dynamics-underlie-variable-ibrutinib-responses-in-waldenstrom-macroglobulinemia/Medxy AIen2026-05-18T17:29:43-07:00Evolution of Tumor Subclones and T-Cell Dynamics Underlie Variable Ibrutinib Responses in Waldenström Macroglobulinemia https://news.medxy.ai/ja/cteph%e6%82%a3%e8%80%85%e3%83%90%e3%83%ab%e3%83%bc%e3%83%b3%e8%82%ba%e5%8b%95%e8%84%88%e5%bd%a2%e6%88%90%e8%a1%93%e5%89%8d%e3%81%ae%e4%ba%8c%e5%89%a4%e4%bd%b5%e7%94%a8%e7%99%82%e6%b3%95%e3%81%a8/Medxy AIja2026-05-18T17:19:23-07:00CTEPH患者バルーン肺動脈形成術前の二剤併用療法と単剤療法の前治療: 合併症と予後の影響 https://news.medxy.ai/vi/lieu-phap-kep-so-voi-don-tri-truoc-khi-thuc-hien-can-thiep-nong-mach-phoi-bang-bong-o-benh-nhan-cteph-tac-dong-doi-voi-bien-co-va-ket-qua/Medxy AIvi2026-05-18T17:18:10-07:00Liệu pháp kép so với đơn trị trước khi thực hiện can thiệp nong mạch phổi bằng bóng ở bệnh nhân CTEPH: Tác động đối với biến cố và kết quả https://news.medxy.ai/dual-versus-monotherapy-pretreatment-before-balloon-pulmonary-angioplasty-in-cteph-effects-on-complications-and-outcomes/Medxy AIen2026-05-18T17:16:34-07:00Dual versus monotherapy pretreatment before balloon pulmonary angioplasty in CTEPH: effects on complications and outcomes https://news.medxy.ai/ja/ntm%e9%99%bd%e6%80%a7%e6%b0%97%e7%ae%a1%e6%94%af%e6%8b%a1%e5%bc%b5%e7%97%87%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8b%e4%b8%8b%e6%b0%97%e9%81%93%e3%81%ae%e8%8f%8c%e5%8f%a2%e7%95%b0%e5%b8%b8%e3%81%af/Medxy AIja2026-05-18T15:45:04-07:00NTM陽性気管支拡張症における下気道の菌叢異常は、NET主導の重症型と関連している https://news.medxy.ai/vi/roi-loan-vi-sinh-duong-ho-hap-duoi-o-benh-phe-quan-dan-no-duong-tinh-voi-ntm-lien-quan-den-cac-the-nang-co-su-chi-phoi-cua-net/Medxy AIvi2026-05-18T15:43:46-07:00Rối loạn vi sinh đường hô hấp dưới ở bệnh phế quản dãn nở dương tính với NTM liên quan đến các thể nặng có sự chi phối của NET https://news.medxy.ai/zh/%e9%9d%92%e5%85%89%e7%9c%bc%e5%bb%b6%e8%bf%9f%e9%9a%8f%e8%ae%bf%e9%80%9a%e5%b8%b8%e4%b8%8e%e8%a7%86%e9%87%8e%e8%bf%9b%e5%b1%95%e6%97%a0%e5%85%b3%ef%bc%8c%e4%bd%86%e5%9c%a8%e6%9b%b4%e6%99%9a%e6%9c%9f/Medxy AIzh2026-05-18T15:43:22-07:00青光眼延迟随访通常与视野进展无关，但在更晚期疾病中较长间隔可能有影响 https://news.medxy.ai/lower-airway-dysbiosis-in-ntm-positive-bronchiectasis-is-linked-to-net-dominant-severe-phenotypes/Medxy AIen2026-05-18T15:42:02-07:00Lower Airway Dysbiosis in NTM-Positive Bronchiectasis Is Linked to NET-Dominant Severe Phenotypes https://news.medxy.ai/ja/%e7%b7%91%e5%86%85%e9%9a%9c%e3%81%ae%e9%81%85%e5%bb%b6%e3%83%95%e3%82%a9%e3%83%ad%e3%83%bc%e3%82%a2%e3%83%83%e3%83%97%e3%81%af%e9%80%9a%e5%b8%b8%e8%a6%96%e9%87%8e%e9%80%b2%e8%a1%8c%e3%81%a8%e9%96%a2/Medxy AIja2026-05-18T15:41:47-07:00緑内障の遅延フォローアップは通常視野進行と関連しないが、より進行した病気では長い間隔が重要である可能性がある https://news.medxy.ai/vi/viec-theo-doi-tre-han-glaucoma-thuong-khong-lien-quan-den-su-tien-trien-cua-truong-thi-nhung-thoi-gian-cho-doi-dai-co-the-quan-trong-trong-benh-nang-hon/Medxy AIvi2026-05-18T15:39:26-07:00Việc Theo Dõi Trễ Hạn Glaucoma Thường Không Liên Quan đến Sự Tiến Triển của Trường Thị, nhưng Thời Gian Chờ Đợi Dài Có Thể Quan Trọng trong Bệnh Nặng Hơn https://news.medxy.ai/delayed-glaucoma-follow-up-was-usually-not-linked-to-visual-field-progression-but-longer-gaps-may-matter-in-more-advanced-disease/Medxy AIen2026-05-18T15:35:24-07:00Delayed Glaucoma Follow-Up Was Usually Not Linked to Visual Field Progression, but Longer Gaps May Matter in More Advanced Disease https://news.medxy.ai/zh/%e4%bc%98%e5%8c%96%e5%9c%b0%e7%90%86%e8%90%8e%e7%bc%a9%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e8%ae%be%e8%ae%a1%ef%bc%9a%e5%af%bc%e5%85%a5%e6%9c%9f%e3%80%81%e5%8d%95%e8%87%82%e6%9e%b6%e6%9e%84%e5%92%8c/Medxy AIzh2026-05-18T15:31:46-07:00优化地理萎缩临床试验设计：导入期、单臂架构和功能性终点的作用 https://news.medxy.ai/ja/%e5%9c%b0%e7%90%86%e8%90%8e%e7%bc%a9%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e8%ae%be%e8%ae%a1%e4%bc%98%e5%8c%96%ef%bc%9a%e5%af%bc%e5%85%a5%e6%9c%9f%e3%80%81%e5%8d%95%e8%87%82%e6%9e%b6%e6%9e%84%e5%92%8c/Medxy AIja2026-05-18T15:30:48-07:00地理萎缩临床试验设计优化：导入期、单臂架构和功能性终点的作用 https://news.medxy.ai/vi/toi-uu-hoa-thiet-ke-thu-nghiem-lam-sang-ve-atrophy-dia-ly-vai-tro-cua-giai-doan-chay-vao-kien-truc-don-tay-va-diem-ket-thuc-chuc-nang/Medxy AIvi2026-05-18T15:29:41-07:00Tối ưu hóa Thiết kế Thử nghiệm lâm sàng về Atrophy Địa lý: Vai trò của Giai đoạn Chạy vào, Kiến trúc Đơn tay và Điểm kết thúc Chức năng https://news.medxy.ai/optimizing-geographic-atrophy-clinical-trial-design-the-role-of-run-in-phases-single-arm-architectures-and-functional-endpoints/Medxy AIen2026-05-18T15:27:35-07:00Optimizing Geographic Atrophy Clinical Trial Design: The Role of Run-In Phases, Single-Arm Architectures, and Functional Endpoints https://news.medxy.ai/ja/glp-1%e6%b8%9b%e9%87%8f%e3%81%8a%e3%82%88%e3%81%b3%e7%b3%96%e5%b0%bf%e7%97%85%e8%96%ac%ef%bc%9a%e7%9c%bc%e5%b0%82%e9%96%80%e5%ae%b6%e3%81%aenaion%e3%83%aa%e3%82%b9%e3%82%af%e3%81%ab%e3%81%a4%e3%81%84/Medxy AIja2026-05-18T15:24:53-07:00GLP-1減量および糖尿病薬：眼専門家のNAIONリスクについての見解 https://news.medxy.ai/vi/thuoc-giam-can-va-dieu-tri-dai-thao-duong-glp-1-nhung-gi-cac-chuyen-gia-ve-mat-noi-ve-nguy-co-naion/Medxy AIvi2026-05-18T15:23:05-07:00Thuốc giảm cân và điều trị đái tháo đường GLP-1: Những gì các chuyên gia về mắt nói về nguy cơ NAION https://news.medxy.ai/zh/glp-1-%e5%87%8f%e8%82%a5%e5%92%8c%e7%b3%96%e5%b0%bf%e7%97%85%e8%8d%af%e7%89%a9%ef%bc%9a%e7%9c%bc%e7%a7%91%e4%b8%93%e5%ae%b6%e5%af%b9-naion-%e9%a3%8e%e9%99%a9%e7%9a%84%e7%9c%8b%e6%b3%95/Medxy AIzh2026-05-18T15:21:42-07:00GLP-1 减肥和糖尿病药物：眼科专家对 NAION 风险的看法 https://news.medxy.ai/glp-1-weight-loss-and-diabetes-drugs-what-eye-specialists-say-about-naion-risk/Medxy AIen2026-05-18T15:19:58-07:00GLP-1 Weight-Loss and Diabetes Drugs: What Eye Specialists Say About NAION Risk